SGLT-2 inhibitors and GLP-1 receptor agonists form an effective strategy for managing MetS in the context of T2DM and their broad effects on metabolism and well-known heart and kidney benefits make them vital parts of modern treatment for cardiometabolic conditions.
Abstract
INTRODUCTION
Metabolic syndrome (MetS) is a cardiometabolic disorder defined by the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III). It is closely linked with type 2 diabetes mellitus (T2DM). The main features of this condition include central obesity, high triglyceride levels, low high-density lipoprotein cholesterol (HDL-C), high blood pressure, and impaired fasting glucose. The bidirectional relationship between MetS and T2DM significantly increases the risk of cardiovascular and metabolic diseases. This review examines the role of sodium-glucose co-transporter-2 (SGLT-2) inhibitors and glucagon-like peptide- 1 (GLP-1) receptor agonists in addressing the different issues associated with MetS. It also discusses their effect on blood sugar control and their benefits for heart and kidney health in people with T2DM.
Methods
This study conducted a thorough review of clinical trials, meta-analyses, and guideline recommendations to gather evidence about how SGLT-2 inhibitors and GLP-1 receptor agonists work and their benefits in managing MetS in T2DM.
Results
Both SGLT-2 inhibitors and GLP-1 receptor agonists have shown improvements in body weight, lipid levels, blood pressure control, and blood sugar management. Furthermore, there is strong evidence supporting their protective effects on heart and kidney health, underlining their importance as key treatments for high-risk patients with T2DM and MetS.
Discussion
Several clinical studies have examined the role of SGLT-2 inhibitors and GLP-1 receptor agonists in addressing MetS, including central obesity, hypertriglyceridemia, low HDL levels, fasting hyperglycaemia, and hypertension.
Conclusion
SGLT-2 inhibitors and GLP-1 receptor agonists form an effective strategy for managing MetS in the context of T2DM. Their broad effects on metabolism and well-known heart and kidney benefits make them vital parts of modern treatment for cardiometabolic conditions.
A clinical pharmacological analysis of current data is presented, discussing the mechanisms of action, clinical efficacy, safety, and strategies for personalized use of SGLT2 inhibitors and GLP-1 RAs in preventing cardiovascular and neurodegenerative complications in patients with type 2 diabetes and metabolic disorder...
E. N. Saykina, A. O. Kenkishvili, M. Maksimov et al.· Terapevt (General Physician)· 0 citations
SGLT2 inhibitor uptake increased substantially during early adoption among medication-treated adults with type 2 diabetes mellitus from 2013 to 2018, and the findings characterize prescribing patterns and prevalent health profiles rather than causal treatment effects.
J. Aboulenein· Natural Resources for Human...· 0 citations
Background: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder associated with substantial cardiovascular and renal complications. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as important therapeutic agents because of their glucose-lowering effects, weight reduction, and potential ca...
Fathima Ibrahim Abdulla, Abdulmueen Ali Alqahtani, N. S. Sait· SAS Journal of Medicine· 0 citations
Background/Objectives: Poor adherence and persistence to sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a critical issue in the treatment of type 2 diabetes mellitus (T2DM), especially in patients with cardiovascular disease (CVD). We aimed to compare...
M. González-González, M. A. Pedrosa-Naudín, D. Fernández-Lázaro et al.· Pharmaceuticals· 0 citations
AIMS
Cardioprotective glucose-lowering drugs (GLDs) remain underutilised in individuals with Type 2 diabetes (T2D) and cardiovascular disease (CVD). We aimed to estimate the association between sex and socioeconomic status and initiation of cardioprotective GLDs and to identify factors associated with non-initiation of...
E. Calderon, L. Bjerg, A. Isaksen et al.· Diabetes, obesity and metabo...· 0 citations
Evaluating the cardiometabolic effectiveness and safety of SGLT2 inhibitors among adults with T2DM and cardiovascular risk factors in routine clinical practice may help characterize their clinical pharmacology and pharmacovigilance profile in a tertiary-care medical-college setting.
Anand, A. Mittal, M. Kaushik et al.· Adolescência e Saúde· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.